Invivyd, INC. (IVVD) — 10-Q Filings

10-Q Filings (6)

• Invivyd's Revenue Surges, But Going Concern Doubts Linger Amid R&D Shift — Nov 6, 2025 Risk: high
  Invivyd, Inc. reported a significant increase in product revenue, reaching $36.2 million for the nine months ended September 30, 2025, a substantial rise from $
• Invivyd's Revenue Soars 420% on PEMGARDA, But Going Concern Looms — Aug 14, 2025 Risk: high
  Invivyd, Inc. (IVVD) reported a significant increase in product revenue, reaching $11.786 million for the three months ended June 30, 2025, up from $2.264 milli
• Invivyd, Inc. Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Invivyd, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Adagio Therapeutics, Inc., is involved in biological products.
• Invivyd, Inc. Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed its 10-Q for the period ending September 30, 2024. The company, incorporated in Delaware, operates in t
• Invivyd, Inc. Files Q2 2024 10-Q Report — Aug 14, 2024 Risk: medium
  Invivyd, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Adagio Therapeutics, Inc., reported on its financial activities
• Invivyd, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
  Invivyd, Inc. (IVVD) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) filed a 10-Q report for the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX